Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel

• Váldodahkkit: Uta Schilling (Dahkki), Chih‐Hsuan Hsin (Dahkki), Stephane Delahaye (Dahkki), Andreas Krause (Dahkki), Hauke Wuelfrath (Dahkki), Atef Halabi (Dahkki), Jasper Dingemanse (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2022-08-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Selatogrel is a potent and selective reversible P2Y12 receptor antagonist in development for early treatment of acute myocardial infarction via subcutaneous (s.c.) self‐injection. Selatogrel is almost exclusively eliminated via the hepatobiliary route. Hepatic impairment is associated with...